tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alterity Therapeutics Files Annual Report with SEC

Story Highlights
Alterity Therapeutics Files Annual Report with SEC

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Alterity Therapeutics ( (AU:ATH) ) just unveiled an update.

Alterity Therapeutics announced the filing of its Annual Report on Form 20-F with the SEC, including audited financial statements for the year ending June 30, 2025. This filing, along with the XBRL interactive data, is available on their website, reflecting the company’s commitment to transparency and regulatory compliance, which could bolster stakeholder confidence and enhance its industry positioning.

More about Alterity Therapeutics

Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company has demonstrated efficacy in its lead asset, ATH434, through clinical trials for Multiple System Atrophy (MSA), and it operates from Melbourne, Australia, and San Francisco, USA.

YTD Price Performance: 40.0%

Average Trading Volume: 13,444,263

Technical Sentiment Signal: Sell

Current Market Cap: A$128.9M

See more insights into ATH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1